
GLP-1 use tied to 91% lower all-cause death in women with breast cancer and diabetes
A JAMA Network Open study reported a 91% lower relative hazard of death from any cause in women with breast cancer and type 2 diabetes who used GLP-1 drugs versus insulin or metformin. Louis stresses it is observational and the endpoint was all-cause mortality, not breast-cancer death or recurrence, so causation is not shown.



